Zobrazeno 1 - 10
of 20
pro vyhledávání: '"Liuxiang Chu"'
Autor:
Tianyu Zhang, Nuannuan Li, Ru Wang, Yiying Sun, Xiaoyan He, Xiaoyan Lu, Liuxiang Chu, Kaoxiang Sun
Publikováno v:
Drug Delivery, Vol 30, Iss 1 (2023)
AbstractDoxorubicin (DOX), a commonly used anti-cancer drug, is limited by its cardiotoxicity and multidrug resistance (MDR) of tumor cells. Epigallocatechin gallate (EGCG), a natural antioxidant component, can effectively reduce the cardiotoxicity o
Externí odkaz:
https://doaj.org/article/03145bf4157f4b49a8c3258f69c1f6ec
Autor:
Ru Wang, Nuannuan Li, Tianyu Zhang, Yiying Sun, Xiaoyan He, Xiaoyan Lu, Liuxiang Chu, Kaoxiang Sun
Publikováno v:
Drug Delivery, Vol 30, Iss 1 (2023)
AbstractMitoxantrone (MX) can induce the immunogenic-cell death (ICD) of tumor cells and activate anti-tumor immune responses. However, it can also cause high expression of indole amine 2, 3-dioxygenase (IDO) during ICD, leading to T-cell apoptosis a
Externí odkaz:
https://doaj.org/article/2fb7697ded2b4d45b98cd7482ceb1b6d
Autor:
Siqi Wang, Yawen Yu, Aiping Wang, Xinliu Duan, Yuchen Sun, Liangxiao Wang, Liuxiang Chu, Yanan Lv, Nan Cui, Xuesong Fan, Chunjie Sha, Lixiao Xu, Kaoxiang Sun
Publikováno v:
Frontiers in Pharmacology, Vol 13 (2022)
Introduction: Temozolomide (TMZ) is the first-line drug for glioblastoma (GBM), but it is limited in clinical use due to the drug resistance, poor brain targeting, and side effects. Temozolomide hexadecyl ester (TMZ16e), a TMZ derivative with high li
Externí odkaz:
https://doaj.org/article/b5f2b9cb00fc49be8741c1f10b9f962a
Autor:
Shengnan Tang, Aiping Wang, Xiuju Yan, Liuxiang Chu, Xiucheng Yang, Yina Song, Kaoxiang Sun, Xin Yu, Rongxia Liu, Zimei Wu, Peng Xue
Publikováno v:
Drug Delivery, Vol 26, Iss 1, Pp 700-707 (2019)
Efficient delivery of brain-targeted drugs is highly important for successful therapy in Parkinson’s disease (PD). This study was designed to formulate borneol and lactoferrin co-modified nanoparticles (Lf-BNPs) encapsulated dopamine as a novel dru
Externí odkaz:
https://doaj.org/article/88fa8751d7d749edafc991324c85bb2a
Autor:
Hongjie Mu, Yiyun Wang, Yongchao Chu, Ying Jiang, Hongchen Hua, Liuxiang Chu, Kaili Wang, Aiping Wang, Wanhui Liu, Youxin Li, Fenghua Fu, Kaoxiang Sun
Publikováno v:
Drug Delivery, Vol 25, Iss 1, Pp 1372-1383 (2018)
Bevacizumab is an anti-vascular endothelial growth factor drug that can be used to treat choroidal neovascularization (CNV). Bevacizumab-loaded multivesicular liposomes (Bev-MVLs) have been designed and developed to increase the intravitreal retentio
Externí odkaz:
https://doaj.org/article/dceff8ba67254f029ba91f21f1ea234d
Autor:
Liuxiang Chu, Aiping Wang, Ling Ni, Xiuju Yan, Yina Song, Mingyu Zhao, Kaoxiang Sun, Hongjie Mu, Sha Liu, Zimei Wu, Chunyan Zhang
Publikováno v:
Drug Delivery, Vol 25, Iss 1, Pp 1634-1641 (2018)
Glioblastoma is the most common malignant brain tumor. Efficient delivery of drugs targeting glioblastomas remains a challenge. Ephrin type-A receptor 3 (EPHA3) tyrosine kinase antibody-modified polylactide-co-glycolide (PLGA) nanoparticles (NPs) wer
Externí odkaz:
https://doaj.org/article/08711b245c7d47d19999f4fde88557be
Publikováno v:
Pakistan Journal of Pharmaceutical Sciences; Jan2024, Vol. 37 Issue 1, p107-113, 7p
Autor:
Yawen Yu, Aiping Wang, Siqi Wang, Yuchen Sun, Liuxiang Chu, Lin Zhou, Xiaoyue Yang, Xincui Liu, Chunjie Sha, Kaoxiang Sun, Lixiao Xu
Publikováno v:
Molecular Pharmaceutics. 19:1219-1229
Temozolomide (TMZ) is a standard-of-care chemotherapeutic drug for the treatment of glioblastoma (GBM), but TMZ-acquired resistance limits its therapeutic effect. In this study, TMZ-loaded gold nanoparticles (TMZ@GNPs) with anti-EphA3 modification on
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a7bb7b772bf988903436f5d1b6a0895a
https://doi.org/10.1021/acs.molpharmaceut.2c00083
https://doi.org/10.1021/acs.molpharmaceut.2c00083
Autor:
Liangxiao Wang, Chunjie Sha, Yawen Yu, Liuxiang Chu, Kaoxiang Sun, Aiping Wang, Ronglin Kan, Junping Han, Xinran Xi
Publikováno v:
Journal of Pharmaceutical Sciences. 110:3431-3438
Temozolomide is a first-line therapeutic drug for glioblastoma (GBM), and it has a low solubility, short biological half-life, and resistance to drug limits in clinical applications. Therefore, it is necessary to find more effective anti-tumor drugs
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3178a807eff4e2ebe6059e896743884b
https://doi.org/10.1016/j.xphs.2021.06.025
https://doi.org/10.1016/j.xphs.2021.06.025
Publikováno v:
Pharmaceutical Development and Technology. 24:1229-1235
Exenatide (EX), a glucagon-like peptide-1 receptor agonist, is used to treat diabetes mellitus. However, its short half-life necessitates frequent administration and fluctuations in its plasma concentration may cause adverse effects. Previously, we d
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ea4584fcce548aa634921b337d6972c1
https://doi.org/10.1080/10837450.2019.1651857
https://doi.org/10.1080/10837450.2019.1651857